Diabetes, Hypertension
Conditions
Keywords
diabetes, hypertension, adherence, implementation, medications, organization of care
Brief summary
Background: Good blood pressure (BP) control among patients with diabetes is essential in preventing diabetes complications and has been found to be not only cost-effective but cost-saving. Nonetheless, over 25% of VA patients with diabetes do not have adequate BP control. Among these poorly controlled patients, over 65% have problems with medication adherence or inadequate intensification of medications. We therefore propose a partnership with the VA Pharmacy Benefits Management (PBM) Office and VISN 11 to evaluate a tailored clinical pharmacist-based intervention to improve medication management, adherence and BP control. Objectives: The specific objectives of this implementation study are: 1) To evaluate the effects of the intervention on blood pressure (primary outcome) and glycemic and lipid control (secondary outcomes); 2) To assess the impact of the intervention on patients' adherence to blood pressure, anti-hyperglycemic, and lipid-lowering regimens, and intensity of these regimens; 3) To evaluate the cost-effectiveness of the intervention compared to usual care; 4) To evaluate the level of attainment of intervention implementation, examine the process of intervention implementation, and determine the potential for sustainability.
Detailed description
Background: Good blood pressure (BP) control among patients with diabetes is essential in preventing diabetes complications and has been found to be not only cost-effective but cost-saving. Nonetheless, over 25% of VA patients with diabetes do not have adequate BP control. Among these poorly controlled patients, over 65% have problems with medication adherence or inadequate intensification of medications. We therefore propose a partnership with the VA Pharmacy Benefits Management (PBM) Office and VISN 11 to evaluate a tailored clinical pharmacist-based intervention to improve medication management, adherence and BP control. Objectives: The specific objectives of this implementation study are: 1) To evaluate the effects of the intervention on blood pressure (primary outcome) and glycemic and lipid control (secondary outcomes); 2) To assess the impact of the intervention on patients' adherence to blood pressure, anti-hyperglycemic, and lipid-lowering regimens, and intensity of these regimens; 3) To evaluate the cost-effectiveness of the intervention compared to usual care; 4) To evaluate the level of attainment of intervention implementation, examine the process of intervention implementation, and determine the potential for sustainability. Methods: In this cluster randomized implementation trial, we will proactively identify, using clinical automated data, all diabetes patients within 3 VA sites who have poor blood pressure control and either poor refill adherence or insufficient medication intensification. (NIDDK R18 funds 2 non-VA sites.) Adherence and treatment intensification patterns will also be evaluated for glycemia and lipids if either of these risk factors is poorly controlled. Clinical pharmacists, trained in motivational interviewing techniques and guided by computerized adherence modules, will identify barriers to medication adherence and provide adherence counseling. They will also be authorized to change and titrate medications following site-specific algorithms. Patients in the non-intervention (control) teams will receive usual care. Blood pressure control and refill adherence will be assessed 6-months after the end of the intervention period. We will also conduct a formative evaluation during the course of the study and assess implementation attainment and potential for dissemination. Status: Data analysis complete. (Enrollment numbers are for VA and non-VA sites \[control and intervention\].)
Interventions
Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
Sponsors
Study design
Eligibility
Inclusion criteria
VA inclusion criteria 1. Must be a veteran at a study site; 2. Have a diagnosis of diabetes; 3. Meet blood pressure, medication adherence and intensification requirements (as determined by the study team)
Exclusion criteria
VA Exclusion 1. Dementia 2. Traumatic brain injury 3. Pregnancy 4. Age \<18 or \>100
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Systolic Blood Pressure | 6 months prior to 6 months after the intervention period |
Secondary
| Measure | Time frame |
|---|---|
| A1c Control | 12 months after intervention period |
| LDL Control | 12 months after invention period |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Pharmacist Management Eligible patients assigned to - adherence counseling and medication management delivered by a clinical pharmacist trained in behavioral counseling approaches (motivational interviewing)
Clinical pharmacist-based intervention: Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms | 1,797 |
| Usual Care Eligible patients receive usual care | 2,303 |
| Total | 4,100 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Pharmacist did not activate patient | 522 | 0 |
Baseline characteristics
| Characteristic | Pharmacist Management | Usual Care | Total |
|---|---|---|---|
| Age, Continuous | 65.3 years STANDARD_DEVIATION 11.7 | 65.3 years STANDARD_DEVIATION 12.1 | 65.3 years STANDARD_DEVIATION 11.9 |
| Region of Enrollment United States | 1797 participants | 2303 participants | 4100 participants |
| Sex: Female, Male Female | 547 Participants | 721 Participants | 1268 Participants |
| Sex: Female, Male Male | 1250 Participants | 1582 Participants | 2832 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 2,319 | 0 / 2,303 |
| serious Total, serious adverse events | 0 / 2,319 | 0 / 2,303 |
Outcome results
Change in Systolic Blood Pressure
Time frame: 6 months prior to 6 months after the intervention period
Population: intention to treat analysis
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Pharmacist Management | Change in Systolic Blood Pressure | -8.9 mmHg |
| Usual Care | Change in Systolic Blood Pressure | -9.0 mmHg |
A1c Control
Time frame: 12 months after intervention period
Population: Includes only participants with an A1c in the 12 months after the intervention period.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Pharmacist Management | A1c Control | 7.4 percentage of total hemoglobin | Standard Deviation 1.4 |
| Usual Care | A1c Control | 7.6 percentage of total hemoglobin | Standard Deviation 1.6 |
LDL Control
Time frame: 12 months after invention period
Population: Includes only participants with a LDL in the 12 months after the intervention period.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Pharmacist Management | LDL Control | 89.1 mg/dl | Standard Deviation 31.1 |
| Usual Care | LDL Control | 87.8 mg/dl | Standard Deviation 32.9 |